Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities

C. Würnschimmel, M. Wenzel, C. Collà Ruvolo, L. Nocera, Z. Tian, F. Saad, A. Briganti, SF. Shariat, P. Mandel, FKH. Chun, D. Tilki, M. Graefen, PI. Karakiewicz

. 2021 ; 39 (10) : 3781-3787. [pub] 20210512

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012183

PURPOSE: To assess the effect of race/ethnicity in cancer-specific mortality (CSM) adjusted for other-cause mortality (OCM) in metastatic prostate cancer patients (mPCa) treated with external beam radiotherapy (EBRT) to the prostate. METHODS: We relied on the Surveillance, Epidemiology, and End Results (SEER) database to identify Caucasian, African-American, Hispanic/Latino and Asian mPCa patients treated by EBRT between 2004 and 2016. Cumulative incidence plots displayed CSM after adjustment for OCM according to race/ethnicity. Propensity score matching accounted for patient age, prostate-specific antigen, clinical T and N stages, Gleason Grade Groups and M1 substages. OCM adjusted multivariable analyses tested for differences in CSM in African-Americans, Hispanic/Latinos and Asians relative to Cauacasians. RESULTS: After 3:1 propensity score matching and OCM adjustment, Asians exhibited lower CSM at 60 and 120 months (48.2 and 60.0%, respectively) compared to Caucasians (66.7 and 79.4%, respectively, p < 0.001). In OCM adjusted multivariable analyses, Asian race/ethnicity was associated with lower CSM (HR 0.66, CI 0.52-0.83, p < 0.001). Conversely, African-American and Hispanic/Latino race/ethnicity did not affect CSM. OCM rates were comparable between examined races/ethnicities. CONCLUSION: In the setting of mPCa treated with EBRT, Asians exhibit lower CSM than Caucasians, African-Americans and Hispanic/Latinos. This observation may warrant consideration in prognostic stratification schemes for newly diagnosed mPCa patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012183
003      
CZ-PrNML
005      
20220506130218.0
007      
ta
008      
220425s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00345-021-03720-7 $2 doi
035    __
$a (PubMed)33978812
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Würnschimmel, Christoph $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. c.wuernschimmel@gmail.com $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada. c.wuernschimmel@gmail.com $1 https://orcid.org/0000000178914791
245    10
$a Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities / $c C. Würnschimmel, M. Wenzel, C. Collà Ruvolo, L. Nocera, Z. Tian, F. Saad, A. Briganti, SF. Shariat, P. Mandel, FKH. Chun, D. Tilki, M. Graefen, PI. Karakiewicz
520    9_
$a PURPOSE: To assess the effect of race/ethnicity in cancer-specific mortality (CSM) adjusted for other-cause mortality (OCM) in metastatic prostate cancer patients (mPCa) treated with external beam radiotherapy (EBRT) to the prostate. METHODS: We relied on the Surveillance, Epidemiology, and End Results (SEER) database to identify Caucasian, African-American, Hispanic/Latino and Asian mPCa patients treated by EBRT between 2004 and 2016. Cumulative incidence plots displayed CSM after adjustment for OCM according to race/ethnicity. Propensity score matching accounted for patient age, prostate-specific antigen, clinical T and N stages, Gleason Grade Groups and M1 substages. OCM adjusted multivariable analyses tested for differences in CSM in African-Americans, Hispanic/Latinos and Asians relative to Cauacasians. RESULTS: After 3:1 propensity score matching and OCM adjustment, Asians exhibited lower CSM at 60 and 120 months (48.2 and 60.0%, respectively) compared to Caucasians (66.7 and 79.4%, respectively, p < 0.001). In OCM adjusted multivariable analyses, Asian race/ethnicity was associated with lower CSM (HR 0.66, CI 0.52-0.83, p < 0.001). Conversely, African-American and Hispanic/Latino race/ethnicity did not affect CSM. OCM rates were comparable between examined races/ethnicities. CONCLUSION: In the setting of mPCa treated with EBRT, Asians exhibit lower CSM than Caucasians, African-Americans and Hispanic/Latinos. This observation may warrant consideration in prognostic stratification schemes for newly diagnosed mPCa patients.
650    _2
$a černoši nebo Afroameričané $x statistika a číselné údaje $7 D001741
650    _2
$a senioři $7 D000368
650    _2
$a Američané asijského původu $x statistika a číselné údaje $7 D001213
650    _2
$a nádory kostí $x etnologie $x mortalita $x sekundární $7 D001859
650    _2
$a karcinom $x etnologie $x mortalita $x radioterapie $x sekundární $7 D002277
650    _2
$a Hispánci a Latinoameričané $x statistika a číselné údaje $7 D006630
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mortalita $x etnologie $7 D009026
650    _2
$a tendenční skóre $7 D057216
650    _2
$a nádory prostaty $x etnologie $x mortalita $x patologie $x radioterapie $7 D011471
650    12
$a radioterapie $7 D011878
650    _2
$a program SEER $7 D018426
650    _2
$a míra přežití $7 D015996
650    _2
$a běloši $x statistika a číselné údaje $7 D044465
655    _2
$a časopisecké články $7 D016428
700    1_
$a Wenzel, Mike $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Collà Ruvolo, Claudia $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada $u Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy
700    1_
$a Nocera, Luigi $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada $u Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Tian, Zhe $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
700    1_
$a Saad, Fred $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
700    1_
$a Briganti, Alberto $u Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Departments of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
700    1_
$a Mandel, Philipp $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Chun, Felix K H $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Tilki, Derya $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany $u Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Graefen, Markus $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
773    0_
$w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 39, č. 10 (2021), s. 3781-3787
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33978812 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130211 $b ABA008
999    __
$a ok $b bmc $g 1789679 $s 1163384
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 39 $c 10 $d 3781-3787 $e 20210512 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace